Close X
Saturday, November 30, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

New housing coming to southern Vancouver Island

New housing coming to southern Vancouver Island
The homes will be split between Saanich and Central Saanich, with construction expected to begin this spring and summer.

New housing coming to southern Vancouver Island

Rising COVID trend amid vaccine supply concerns

Rising COVID trend amid vaccine supply concerns
The federal government had no immediate comment on the report, but did say possible new European Union restrictions on vaccine shipments would not affect Canada.

Rising COVID trend amid vaccine supply concerns

Businesses want extension of wage, rent subsidies

Businesses want extension of wage, rent subsidies
The government has targeted June 5 for an end to the federal wage and rent subsidies, and this week extended applications for a popular loan program to the same time.

Businesses want extension of wage, rent subsidies

Canada imposes new sanctions on Russian officials

Canada imposes new sanctions on Russian officials
Garneau says the sanctions are also a response to Russian officials having detained thousands of protesters in recent weeks.

Canada imposes new sanctions on Russian officials

New sketch done of Victoria boy missing 30 years

New sketch done of Victoria boy missing 30 years
The Victoria Police Department and members of Dunahee's family released a new age-enhanced photo today of what he might look like as a 34-year-old.

New sketch done of Victoria boy missing 30 years

B.C. premier to announce vaccine partnerships

B.C. premier to announce vaccine partnerships
A government release says they will be announcing new partnerships for the immunization plan.

B.C. premier to announce vaccine partnerships